Irinotecan-induced interstitial pneumonia

Lancet Oncology

Volumn 5, Issue 5, 2004, Pages 322-324

  Michielin, O ^a   Udry, E ^a   Periard D ^a   Matzinger, O ^a   Lobrinus, J A ^b   Stupp, R ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY INSTITUTE OF PATHOLOGY   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; IRINOTECAN; TEMOZOLOMIDE;

ADULT; ARTICLE; AUTOPSY; BLOOD GAS ANALYSIS; CASE REPORT; CAUSE OF DEATH; COMPUTER ASSISTED TOMOGRAPHY; DRUG TOLERABILITY; FIBEROPTIC BRONCHOSCOPY; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; INTERSTITIAL PNEUMONIA; LABORATORY TEST; MALE; MYOPATHY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SYMPTOMATOLOGY; THORAX RADIOGRAPHY;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CAMPTOTHECIN; DACARBAZINE; DIAGNOSIS, DIFFERENTIAL; FRONTAL LOBE; GLIOBLASTOMA; HUMANS; LUNG DISEASES, INTERSTITIAL; MALE;

EID: 2142809687     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(04)01471-8     Document Type: Article

References (7)

1. Stupp R, Ostermann S, Calderoni A, et al. Temozolomide and irinotecan for primary brain tumors: a dose escalation study. Proc Am Soc Clin Oncol 2003; 415 (abstr).
2. Rosenow EC Myers JL Swensen SJ Pisani RJ. Drug-induced pulmonary disease: an update Chest 102 1992 239-250
3. Cunningham AC Zhang JG Moy JV et al. A comparison of the antigen-presenting capabilities of class II MHC-expressing human lung epithelial and endothelial cells Immunology 91 1997 458-463
4. Semenzato G Adami F Maschio N Agostini C. Immune mechanisms in interstitial lung diseases Allergy 55 2000 1103-1120
5. Rothenberg ML Eckardt JR Kuhn JG et al. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer J Clin Oncol 14 1996 1128-1135
6. Pitot HC Wender DB O'Connell MJ et al. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma J Clin Oncol 15 1997 2910-2919
7. Madarnas Y Webster P Shorter AM Bjarnason GA. Irinotecan associated pulmonary toxicity Anticancer Drugs 11 2000 709-713